EFFICACY RESULTS: 5-YEAR FOLLOW-UP

IMPROVED OVERALL SURVIVAL WAS MAINTAINED IN PATIENTS TREATED WITH VYXEOS VS CONVENTIONAL CHEMOTHERAPY* AFTER A 5-YEAR FOLLOW UP1

OVERALL SURVIVAL: 5-YEAR RESULTS1,2

efficacy-5results-1
Adapted from Lancet, et al (2021) and the VYXEOS Product Monograph.
efficacy-5results-1
Adapted from Lancet, et al (2021) and the VYXEOS Product Monograph.

More than twice as many patients treated with VYXEOS were alive after 5 years than those treated with conventional chemotherapy2*

POST-HOC ANALYSIS SUGGESTS THAT OVERALL SURVIVAL WAS MAINTAINED ABOVE 50% AT 5 YEARS IN PATIENTS WHO RECEIVED VYXEOS AND UNDERWENT HSCT1,2

OVERALL SURVIVAL LANDMARKED FROM DATE OF HSCT1,2

efficacy-5results-2
Adapted from Lancet, et al (2021) and the VYXEOS Product Monograph.
efficacy-5results-2
Adapted from Lancet, et al (2021) and the VYXEOS Product Monograph.

HSCT was reached by 35% of patients     
treated with VYXEOS (n = 53/153)   
vs     
25% of patients    
receiving conventional chemotherapy* (n = 39/151)2

vyexos_down.png

49 %

Reduced relative risk of death for patients receiving transplant when treated with VYXEOS vs conventional chemotherapy2,3*

POST-HOC ANALYSIS OF PATIENTS WHO ACHIEVED CR OR CRi1

OVERALL SURVIVAL WAS GREATER AT 5 YEARS IN PATIENTS WITH A CR OR CRi AND TREATED WITH VYXEOS VS CONVENTIONAL CHEMOTHERAPY1*

efficacy-5-result-3
Adapted from Lancet, et al (2021).
efficacy-5-result-3
Adapted from Lancet, et al (2021).
vyexos_survival_person.png

PATIENTS WITH A CR OR CRi TREATED WITH VYXEOS ACHIEVED A HIGHER RATE OF HSCT and a LONGER MEDIAN OS from date of transplant vs conventional chemotherapy.4

CI: Confidence interval

CRi: Complete response with incomplete platelet or neutrophil recovery

HR: Hazard ratio

HSCT: Hematopoietic stem cell transplantation

OS: Overall survival

*Conventional chemotherapy includes the 7+3/5+2 regimen for induction and consolidation, using cytarabine and daunorubicin.3

References: 1. Lancet JE, Uy GL, Newell LF, et al. CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukemia: 5-year results of a randomized, open-label, multicentre, phase 3 trial. Lancet Hematol 2021;8:e481–491. 2. Current VYXEOS® Product Monograph, Jazz Pharmaceuticals Canada, Inc. 3. Lancet JE, Uy GL, Cortes JE, et al. CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J Clin Oncol 2018;36:2684–2692. 4. Faderl S, Uy GL, Schiller GJ, et al. Outcomes in older patients with newly diagnosed, high-risk/secondary AML (sAML) who achieve remission with CPX-351 versus 7+3 Induction. Presented at the ISAL XVII 2019.

CA-VYX-2400013-E | March 2024